UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Post hoc analysis of the Exenatide‐PD trial—Factors that predict response

Athauda, D; Maclagan, K; Budnik, N; Zampedri, L; Hibbert, S; Aviles-Olmos, I; Chowdhury, K; ... Foltynie, T; + view all (2019) Post hoc analysis of the Exenatide‐PD trial—Factors that predict response. European Journal of Neuroscience , 49 (3) pp. 410-421. 10.1111/ejn.14096. Green open access

[thumbnail of Article]
Preview
Text (Article)
Foltynie_EJNMANUSCRIPT revision1.pdf - Accepted Version

Download (713kB) | Preview
[thumbnail of Tables]
Preview
Text (Tables)
Foltynie_EJNTABLES.pdf - Accepted Version

Download (431kB) | Preview

Abstract

Exenatide, a glucagon-like peptide-1 agonist and a licensed treatment for Type 2 diabetes significantly reduced deterioration in motor symptoms in patients with Parkinson's disease in a randomised, placebo-controlled trial. Additionally, there were trends favouring the exenatide group in assessments of non-motor symptoms, cognition and quality of life. The aim of this exploratory post-hoc analysis was to generate new hypotheses regarding (1) whether candidate baseline factors might predict the magnitude of response to exenatide and (2) whether the beneficial effects of exenatide reported for the overall population are consistent in various subgroups of patients. Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort. Potential treatment by subgroup interactions for changes in; motor severity, non-motor symptoms, cognition and quality of life after 48-weeks treatment with exenatide were evaluated among post-hoc subgroups defined by age, motor phenotype, disease duration, disease severity, BMI and insulin resistance. In the subgroup analyses, exenatide once-weekly was associated with broadly improved outcome measures assessing motor severity, non-motor symptoms, cognition and quality of life across all subgroups, however tremor-dominant phenotype and lower MDS-UPDRS Part-2 scores predicted greatest motor response to exenatide and there was an indication that patients with older age of onset and disease duration over 10 years responded less well. While patients with a range of demographic and clinical factors can potentially benefit from exenatide once-weekly, these data support an emphasis towards recruiting patients at earlier disease in future planned clinical trials of GLP-1 receptor agonists in PD. This article is protected by copyright. All rights reserved.

Type: Article
Title: Post hoc analysis of the Exenatide‐PD trial—Factors that predict response
Location: France
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/ejn.14096
Publisher version: http://dx.doi.org/10.1111/ejn.14096
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Glucagon-like peptide-1 agonist, Parkinson's disease, clinical trial, exenatide
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: https://discovery.ucl.ac.uk/id/eprint/10054567
Downloads since deposit
439Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item